Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.

Autor:	Thibault T; Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France.; Clinical Investigation Center, INSERM CIC-EC 1432, University Hospital Dijon-Burgundy, Dijon, France., Rajillah A; Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France., Bourredjem A; Clinical Investigation Center, INSERM CIC-EC 1432, University Hospital Dijon-Burgundy, Dijon, France., Corneloup M; Clinical Investigation Center, INSERM CIC-EC 1432, University Hospital Dijon-Burgundy, Dijon, France., Maurier F; Department of Internal Medicine and Clinical Immunology, Hôpital Robert Schuman, Metz-Vantoux, 57070, France., Wahl D; Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Inserm UMR_S 1116, CHRU de Nancy, University of Lorraine, Nancy, France., Muller G; Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France., Aumaitre O; Department of Internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont-Ferrand, France., Sève P; Department of Internal Medicine, Lyon University Hospital, Hôpital Croix Rousse, Lyon, France.; Research on Healthcare Performance, INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France., Blaison G; Department of Internal Medicine, Hôpital Louis Pasteur, Colmar, France., Besancenot JF; Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France., Martin T; Internal Medicine and Clinical Immunology Department, Centre National de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Strasbourg University Hospital, Strasbourg, France., Magy-Bertrand N; Department of Internal Medicine, University Hospital Jean Minjoz, Besançon, France., Samson M; Internal Medicine and Clinical Immunology Unit, University Hospital Dijon-Burgundy, Dijon, France., Arnaud L; Department of Rheumatology, Centre National de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.; INSERM UMR-S 1109, Strasbourg, France., Amoura Z; Department of Internal Medicine, National Referral Center for Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome, Pitié-Salpêtrière University Hospital, Paris, France., Devilliers H; Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France.; Clinical Investigation Center, INSERM CIC-EC 1432, University Hospital Dijon-Burgundy, Dijon, France.
Jazyk:	angličtina
Zdroj:	Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 May 02; Vol. 63 (5), pp. 1447-1455.
DOI:	10.1093/rheumatology/kead407
Abstrakt:	Objectives: To measure the association between SLE remission and scores of patients-reported outcome (PRO) measures. Methods: We performed a prospective cohort study of SLE patients with a 2-year follow-up, using Lupus Patient-Reported Outcome (LupusPRO), Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus Quality of Life (SLEQOL) and 36-item Short Form (SF-36) questionnaires. Remission was defined as remission off treatment (ROFT) and remission on treatment (RONT) according to the definitions of remission in SLE consensus. Mixed models accounting for repeated measures were used to compare groups as follow: ROFT and RONT vs no remission and lupus low disease activity state (LLDAS) vs no LLDAS. Results: A total of 1478 medical visits and 2547 PRO questionnaires were collected during the follow-up from the 336 recruited patients. A between-group difference in PRO scores reaching at least 5 points on a 0-100 scale was obtained in the following domains: lupus symptoms (LLDAS: +5 points on the 0-100 scale, RONT: +9, ROFT: +5), lupus medication (LLDAS: +5, RONT: +8, ROFT: +9), pain vitality (LLDAS: +6, RONT: +9, ROFT: +6) of LupusPRO; role emotional (LLDAS: +5, RONT: +8), role physical (RONT: +7 and ROFT: +7), bodily pain (RONT: +6), mental health (RONT: +5) and social functioning (RONT: +6) of SF-36. In contrast, a between-group difference reaching at least 5 points was not achieved for any of the LupusQoL and SLEQOL domains. Conclusions: RONT, ROFT and LLDAS were associated with significant and clinically relevant higher QoL in most PRO domains of the LupusPRO (disease specific) and SF-36 (generic) questionnaires, but not with LupusQoL and SLEQOL disease-specific questionnaires. (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu